IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1247 
Small font sizeDefault font sizeIncrease font size
Navigate Here
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (325 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

In This Article

 Article Access Statistics
    PDF Downloaded52    
    Comments [Add]    

Recommend this journal


 Table of Contents    
Year : 2021  |  Volume : 53  |  Issue : 5  |  Page : 420-421

Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19

1 Department of Clinical Pharmacology, SAKRA World Hospital, Bengaluru, Karnataka, India
2 Department of Cardiac Surgery, SAKRA World Hospital, Bengaluru, Karnataka, India

Date of Submission29-Jun-2021
Date of Acceptance31-Aug-2021
Date of Web Publication24-Nov-2021

Correspondence Address:
Dr. Chanda Kulkarni
Department of Clinical Pharmacology, SAKRA World Hospital, Bengaluru, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijp.ijp_508_21

Rights and Permissions

How to cite this article:
Kulkarni C, Sadiq A, Gigi A, Devassia A, George G. Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19. Indian J Pharmacol 2021;53:420-1

How to cite this URL:
Kulkarni C, Sadiq A, Gigi A, Devassia A, George G. Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19. Indian J Pharmacol [serial online] 2021 [cited 2023 Jun 5];53:420-1. Available from: https://www.ijp-online.com/text.asp?2021/53/5/420/331081


Hydroxychloroquine (HCQ), use is well-known to treat or prevent malaria and is approved by Food and Drug Administration. It is also approved for the treatment of autoimmune disorders like rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. In early 2020, during the outbreak of pandemic with severe acute respiratory syndrome coronavirus 2 (SARS–CoV-2) infection, the advisory released by the Indian Council of Medical Research (ICMR) and Ministry of Health and Family Welfare which constituted the National Task Force, Government of India, recommended the use of HCQ, against SARS–CoV-2 infection for prophylaxis and treatment to reduce the morbidity and mortality. Although, an established century-old antimalarial drug the advisory from ICMR was based on its proposed in-vitro anti-Covid activity. In this context, HCQ was distributed to Health Care Workers (HCWs) free of cost considering their high risk of exposure to COVID-19.[1]

The HCWs of all categories of our hospital included–doctors, nursing, and paramedical staff including support staff, who volunteered and consented were subjected to routine general clinical examination by physicians for known contraindications to HCQ. They were then distributed a single, course of HCQs free of cost as a prophylactic measure against COVID-19 by our hospital.

Subsequently, a retrospective survey was carried out using questionnaire on the mobile phone WhatsApp platform among HCWs who had collected the HCQ tablets. The primary objective of this quick retrospective survey was to assess the extent of compliance to HCQ and adverse events (AEs) if any to HCQ. This was felt important since it is reported that HCQ has a wide range of adverse reactions.[2],[3] The questionnaire was designed to capture the level of compliance to HCQs as well as the pattern, extent, and severity of AEs through responses to ten-item questionnaires. These responses were analyzed descriptively to assess the level of compliance and profile of AEs to HCQ.

The survey forms were sent through WhatsApp to 245 HCWs of which 170 (69.38%) responded of which 56.47% had completed the single course of HCQs. There were 49/51 self–reported AEs which were mild to moderate and 2/51 (1.17%) were severe which resolved after discontinuation of HCQ along with appropriate pharmacological treatment, but none were hospitalized. This report is being submitted to add evidence to the existing AE profile observed among non-Covid otherwise healthy subjects who had received HCQ for COVID-19 prophylaxis.

The present survey showed the extent of nonadherence to HCQ prophylaxis among healthy HCWs was close to 50% and was influenced by factors such as mild–severe AEs. While mild AEs were found to be self-limiting the moderately severe cardiac event in one necessitated discontinuation of HCQ. Further, a severe dermatological AE in another subject warranted discontinuation along with pharmacological intervention. However, there was no mortality and none required hospitalization. Therefore, it may be suggested that careful monitoring should be a part of routine management of patients with SARS–CoV-2 infection receiving HCQ either for prophylaxis or treatment in a resource-limited country like India. Further, the studies in more number of subjects, over a longer duration of treatment may help in considering HCQ as a cheaper option for the prophylaxis and/or treatment of SARS–CoV-2 infection.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Advisory on the Use of Hydroxychloroquine – The National Task Force for COVID-19 Constituted by Indian Council of Medical Research Recommends the Use of Hydroxychloroquine – MoHFW; March 22, 2020.  Back to cited text no. 1
Eurosurveillance Editorial Team. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveill 2020;25:200131e.  Back to cited text no. 2
Hydroxychloroquine Side Effects Medically Reviewed by Drugs.com. Available from: www.sakraworldhospital.com. [Last updated on 2020 Apr 26].  Back to cited text no. 3


Print this article  Email this article


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow